Scarica l'app Stockscreener
35.62
1.44%
-0.52
Dopo l'orario di chiusura:
35.64
0.02
+0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$36.14
Aprire:
$36.39
Volume 24 ore:
1.73M
Relative Volume:
0.79
Capitalizzazione di mercato:
$3.30B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-12.72
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-6.88%
1M Prestazione:
+2.09%
6M Prestazione:
-31.00%
1 anno Prestazione:
-33.48%
Intervallo 1D:
$35.55
$37.34
Intervallo di 1 settimana:
$33.03
$38.49
Portata 52W:
$30.04
$67.88
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
35.62 | 3.30B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
William Blair Expects Lower Earnings for CRISPR Therapeutics - MarketBeat
Q2 EPS Forecast for CRISPR Therapeutics Lowered by Analyst - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for CRSP Earnings - MarketBeat
(CRSP) Investment Report - news.stocktradersdaily.com
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks - MSN
Benjamin Edwards Inc. Acquires 12,359 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Illinois Tool Works, Wynn Resorts, Agree Realty, Crispr Therapeutics, Super Micro Computer: Trending by Analysts - MSN
Dimensional Fund Advisors LP Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Bridgefront Capital LLC Invests $680,000 in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
3 Monster Stocks to Hold for the Next 10 Years - The Motley Fool
Crispr Therapeutics (CRSP) Price Target Reduced by Barclays to $42 | CRSP Stock News - GuruFocus
CRISPR Therapeutics (CRSP) Downgraded Amid Market Challenges - GuruFocus
CRISPR Therapeutics (CRSP) Price Target Lowered by Barclays | CRSP Stock News - GuruFocus
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines - Seeking Alpha
Needham & Company LLC Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $81.00 - MarketBeat
Chardan Capital Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $82.00 - MarketBeat
Baker BROS. Advisors LP Has $51.48 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million - Yahoo Finance
CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results - insights.citeline.com
CRISPR Therapeutics (CRSP): Goldman Sachs Lowers Price Target to $47 | CRSP Stock News - GuruFocus
June 27th Options Now Available For CRISPR Therapeutics - Nasdaq
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet - Yahoo Finance
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade) - Seeking Alpha
Promising Developments and Pipeline Expansion at Crispr Therapeutics AG Support Buy Rating - TipRanks
Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRSP: Needham Maintains Buy Rating Despite Target Price Reductio - GuruFocus
Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRS - GuruFocus
Crispr Therapeutics price target lowered to $79 from $80 at BofA - TipRanks
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRSP Stock News - GuruFocus
CRSP: Needham Maintains Buy Rating Despite Target Price Reduction | CRSP Stock News - GuruFocus
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results - Benzinga
CRSP Stock: Analyst Maintains Buy Rating, Lowers Price Target | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Trial Results and Strong Financial Position Support Buy Rating - TipRanks
Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations - TipRanks
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates - MSN
Crispr Therapeutics (CRSP) Upgraded to Buy by Clear Street Analyst | CRSP Stock News - GuruFocus
Crispr Therapeutics upgraded to Buy from Hold at Clear Street - TipRanks
Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating - TipRanks
NKureCRISPR Therapeutics partner to develop off-the-shelf CAR-T therapy - BusinessLine
NkureCrispr Therapeutics partner to co-develop off-the-shelf CAR-T therapy - BusinessLine
NKure Therapeutics and CRISPR Therapeutics Partner to Advance CTX112 for Cancer Treatment in India - APN News
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Nkure Therapeutics And CRISPR Therapeutics Partner To Advance CTX112™ For Cancer Treatment In India - Passionate In Marketing
Decoding CRISPR Therapeutics AG (CRSP): A Strategic SWOT Insight - GuruFocus
CRISPR (CRSP) Reports Wider Losses Amid Revenue Growth - GuruFocus
Crispr Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com
CRISPR Therapeutics AG reports results for the quarter ended March 31Earnings Summary - TradingView
CRISPR Therapeutics AG Reports Q1 2025 EPS of -$1.58 and Revenue of $865K, Missing Estimates - GuruFocus
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):